Linked Life Data

17470857

Source:http://linkedlifedata.com/resource/pubmed/id/17470857

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
2007-5-1
pubmed:abstractText
This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1651-7
pubmed:dateRevised
2007-12-3
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
pubmed:affiliation
New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA.
pubmed:publicationType
Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, N.I.H., Extramural